Hepatocellular carcinoma is a hypermetabolic tumor, and research by Professor Yu and his team found that glutaminase is highly expressed in 80% of patients with hepatocellular carcinoma, and that high glutaminase expression shows some correlation with poor prognosis. Usually, glutaminase is divided into hepatic and renal types, with the hepatic type predominating in normal liver. Professor Yu’s study found that in hepatocellular carcinoma tissue, the renal type was predominant, and patients had the worst prognosis when their glutaminase was abnormally elevated and the phenotype was predominantly renal. They developed a glutaminase scoring system to predict the prognosis of patients with liver cancer, and analyzed the expression of glutaminase in more than 1,000 liver cancer patients through a retrospective study using techniques such as immunohistochemistry and tissue microarrays. They are currently conducting a multicenter, prospective clinical study and expect to have more definitive results within a year or two. When talking about the prognostic role of glutaminase in liver cancer patients, Prof. Yu expressed full confidence. Finally, when talking about the status of liver cancer research in China, Prof. Yu said, “At present, it is rather difficult to clinically classify liver cancer. Especially in China, we have a large number of clinical samples, but due to the problems in clinical study design, we still have relatively few results to communicate in international conferences. Therefore, we young researchers should strive to do our own research well for the benefit of the majority of liver cancer patients.”